Gene:
SERPINE1
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1799889 -817_-816insA, -817_-816insG, 100769710_100769711insA, 100769710_100769711insG, 38802553_38802554insA, 38802553_38802554insG, 4332_4333insA, 4332_4333insG
A > G
5' Flanking
No VIP available CA VA
rs2227631 -989A>G, 100769538A>G, 38802381A>G, 4160A>G
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs2227684 100776931G>A, 11553G>A, 38809774G>A, 656-45G>A, 701-45G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs6092 100771717G>A, 38804560G>A, 43G>A, 6339G>A
G > A
Missense
Ala15Thr
No VIP available No Clinical Annotations available VA
rs7242 *722T>G, 100781445T>G, 16067T>G, 38814288T>G
T > G
3' UTR
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  plasminogen activator inhibitor, type I
Alternate Symbols:  PAI
PharmGKB Accession Id: PA261

Details

Cytogenetic Location: chr7 : q21.3 - q22.1
GP mRNA Boundary: chr7 : 100770379 - 100782547
GP Gene Boundary: chr7 : 100760379 - 100785547
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
antidepressants

Curated Information ?

Publications related to SERPINE1: 3

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008. French Deborah, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenetics and genomics. 2008. Tsai Shih-Jen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction of fibrinolysis and prothrombotic risk factors in neonates, infants and children with and without thromboembolism and underlying cardiac disease. a prospective study. Thrombosis research. 2001. Nowak-Göttl U, et al. PubMed

LinkOuts

HuGE:
SERPINE1
Comparative Toxicogenomics Database:
5054
ModBase:
P05121
HumanCyc Gene:
HS02899
HGNC:
8583

Common Searches